公开(公告)号：US20220071965A1

公开(公告)日：2022-03-10

申请号：US17415902

申请日：2019-12-17

Applicant: Pfizer Inc.

Inventor： Christine Ellen Bulawa ,  James Allan Fleming

IPC: A61K31/423 ,  C12N15/113 ,  A61K31/4245 ,  A61K31/4025 ,  C07K16/18 ,  A61P25/00

Abstract: The present invention relates to pharmaceutical compositions and methods of treatment comprising administering to a patient in need thereof a combination of a benzoxazole derivative transthyretin stabilizer or a pharmaceutically acceptable salt or prodrug thereof and an additional therapeutic agent for the treatment of transthyretin amyloidosis. Particularly, the present invention relates to pharmaceutical compositions and methods of treatment comprising administering to a patient in need thereof 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid or a pharmaceutically acceptable salt or prodrug thereof and one or more additional therapeutic agent for the treatment of transthyretin amyloidosis.

公开(公告)号：US12268669B2

公开(公告)日：2025-04-08

申请号：US17415902

申请日：2019-12-17

Applicant: Pfizer Inc.

Inventor： Christine Ellen Bulawa ,  James Allan Fleming

IPC: A61K31/423 ,  A61K31/4025 ,  A61K31/4245 ,  A61P25/00 ,  C07K16/18 ,  C12N15/113

Abstract: The present invention relates to pharmaceutical compositions and methods of treatment comprising administering to a patient in need thereof a combination of a benzoxazole derivative transthyretin stabilizer or a pharmaceutically acceptable salt or prodrug thereof and an additional therapeutic agent for the treatment of transthyretin amyloidosis. Particularly, the present invention relates to pharmaceutical compositions and methods of treatment comprising administering to a patient in need thereof 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid or a pharmaceutically acceptable salt or prodrug thereof and one or more additional therapeutic agent for the treatment of transthyretin amyloidosis.